Targeted Therapies

  • Author: Gail Wilkes, RNC, ANP-BC, MS, AOCN® (More Info)
  • Section Editor: Marlene SanFilippo, MSN, ARNP, FNP-C, AOCNP®
  • Editors In Chief: Dawn Camp-Sorrell, MSN, FNP, AOCN®; Rebecca Hawkins, MSN, ANP, AOCN®, ACHPN
  • Last Reviewed: 7/9/18 (What's New)


  • Blocking the PARP enzyme halts DNA repair, leading to cell death (Figure 8)
  • Niraparib (Table 49), olaparib (Table 50), and rucaparib (Table 51) are approved PARP inhibitors for patients with advanced ovarian cancer
  • A key nursing measure is counseling patients on the management of fatigue, as a common side effect is anemia

Action required